Delcath Systems Q2 2024 Earnings Call Transcript

Quartr
Provided by Quartr
August 5, 2024

There are 10 speakers on the call.

Operator

Greetings and welcome to Delcat Systems Second Quarter 20 24 Earnings Conference Call. At this time, all participants are in a listen only mode. A brief question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mr.

Operator

David Hoffman, Delcat General Counsel. Thank you, Mr. Hoffman. You may begin.

Speaker 1

Thank you. And once again, welcome to Delacast Systems' Q2 2024 Earnings and Business Highlights Call. With me on the call are Gerard Michel, Chief Executive Officer Sandra Pinnell, Senior Vice President of Finance Kevin Muir, General Manager, Interventional Oncology Boyo Vukovich, Chief Medical Officer and Martha Rooke, Chief Operating Officer. I'd like to begin the call by reading the Safe Harbor statement. This statement is made pursuant to the Safe Harbor for forward looking statements described in the Private Securities Litigation Reform Act of 1995.

Speaker 1

All statements made on this call, with the exception of historical facts, may be considered forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the company believes that expectations and assumptions reflected in these forward looking statements are reasonable, it makes no assurance that such expectations will prove to have been correct. Actual results may differ materially from those expressed or implied in forward looking statements due to various risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those expressed or implied in the forward looking statements, please see Risk Factors detailed in the company's annual report on Form 10 ks, those contained in subsequently filed quarterly reports on Form 10Q as well as in other reports that the company files from time to time with the Securities and Exchange Commission. Any forward looking statements included in this call are made only as of the date of this call.

Speaker 1

We do not undertake any obligation to update or supplement any forward looking Our press release with our Q2 20 Our press release with our Q2 2024 results is available on our website, www.delcap.com, under the Investors section and includes additional details about our financial results. Our website also has our latest SEC filings, which we encourage you to review. A recording of today's call will be available on our website. Now, I would like to turn the call over to Gerard Michel. Gerard, please proceed.

Speaker 2

Thank you everyone for joining. During today's call, we will review DelCap's Q2 financial results, our ongoing commercial activities including projections for both site activation and average treatment rates for the balance of the year, as well as some important medical and clinical updates. In the Q2, Delcat reported $7,800,000 in total revenue, including $6,600,000 in U. S. Revenue from HESATO and $1,200,000 in European revenue for Chemocept.

Speaker 2

As we have previously described, the key drivers of our revenue ramp in the U. S. Are center activation and once activated the average number of treatment centers per average number of treatments per center. From a high level, we are thrilled with our overall progress in terms of our ramp and we're very, very encouraged about what the coming quarters will bring. Now to be specific, in terms of site activation, we ended the Q2 with 7 active sites.

Speaker 2

And as of today, we have 8 active sites. While this fell just below the number we projected in our last call, the treatment rate of just under 2 per month percenter is well ahead of our previously communicated projected rate. I'd like to dig a little deeper into both metrics and turn first to signed center activation. While activation has been a bit slower at some centers than anticipated, there is no systemic reason for the increase in time for center activation, but instead it's just simply a function of the complexity of activating a center given the number of stakeholders involved. It's important to note that we haven't seen any center in the activation process halt the process.

Speaker 2

From our ongoing conversations with the centers, we are confident that all the centers that are in process, which today stands at over 20 centers beyond our active currently active sites will be active in 2025. The 8 active centers include Moffitt Cancer Center, Stanford University Cancer Center, Thomas Jefferson University, University of Wisconsin, Regional One Health or University of Tennessee, UCLA Cancer Center, the University of North Carolina Hospital and HonorHealth Scottsdale. 2 additional centers having completed all the required preceptorships and have each scheduled their first treatment this month. Assuming no cancellations, we should end the August with 10 treating centers. An additional 4 centers have completed the necessary steps to conduct their 1st commercial treatment under the guidance of Procter and are currently in the process of identifying and scheduling a patient for proctor treatment with hepatoKIT.

Speaker 2

As I've mentioned in the past, that can be accomplished scheduling algorithm, given all the member all the proctors that need to arrive as well as that fit with the patient's needs as well. Further, 8 centers have currently completed a portion of the preceptorship requirement. To date, we have had over 130 perfusionists, anesthesiologists and interventional radiologists attend preceptorships representing over 20 institutions in the U. S. With some institutions sending multiple health care providers.

Speaker 2

We are confident that the 12 centers that are currently in the process of activating will successfully activate within the next 6 months. Now I'd like to dig a little into a second metric, average treatments per center, has been higher than we projected during our last call. Adjusting for the data center activation, the average treatment by center was just under 2 per month in the second quarter. Not surprisingly, some centers have notably greater volumes than others. But given the commitment required to become a REMS certified active treating center, we believe that the vast majority of treatment centers either currently active or undergoing the activation process will become meaningful revenue contributors.

Speaker 2

We started the Q3 with 7 active sites with 8 active sites as of today. As I mentioned before, we anticipate we can end the 3rd quarter with 12 active sites. We expect to reach 15 early in the Q4 and anticipate having 20 centers by the end of 2024 or shortly thereafter. While HEBSIRA treatments in the 2nd quarter averaged just under 2 treatments per month for the active treating centers adjusted for when centers started treating patients. We estimate treatments will average between 1.5 to 2 treatments per center for the balance of the year, somewhat under the 2nd quarter average, but above what we projected in our last call.

Speaker 2

This is based in part on a pattern we are seeing where some centers treated initial group of patients and then paused for a month or more before treating additional patients. Besides assessing patient outcomes, the pause provides an opportunity for our centers to evaluate the explanation of benefits from payers before approving a study for our patients. As many of you know, this is a common dynamic for the rollout of premium innovative new procedures and therapies within hospitals. Even in situations such as ours, where the product has the benefit of a product specific J code, which greatly reduces risk of underpayment. Some of you may have seen this morning's press release in which we shared that on August 1, we were informed by CMS that we were granted new technology add on payment status for HEPSADA effective for September effective for starting October 1, 2024.

Speaker 2

This additional payment under NTAP designation will help cover the costs associated with the treatment for the small percentage of Medicare patients that might require an inpatient stay. As a reminder, most patients do not end up being billed as inpatient and thus for those Medicare billed patients in an outpatient basis, the product is reimbursed to the hospital under J code at ASP ++6%. Given the pace of revenue ramp, we expect that we continue to expect that we will achieve $10,000,000 in quarterly U. S. Revenue by the Q4 of this year, which is expected to trigger approximately $25,000,000 in cash proceeds from the exercise of the remaining tranche of warrants that were issued as part of our financing in March 2020 3.

Speaker 2

HEEMO SAD sales in Europe have increased over 100% over the same period prior year. Majority of the growth was from Germany and is a result of having a dedicated commercial presence in the market for over a year. We're in the process of submitting for reimbursement in the UK and we now understand that that review will take place next year. While we estimate approximately 40% of all metastatic UV melanoma patients in the Netherlands are being treated with ChemoSat, those patients are almost all being treated as part of the ongoing SHOPAN trial. We have started commercial sales in Sweden, but expect most patients enroll in an IIT we are sponsoring there, looking at sequencing ipinib with ChemoSat, which I will describe in greater detail in a moment.

Speaker 2

We are early in the process of identifying and opening commercial centers in France, Italy and Spain. We believe it is important to have multiple treating centers in all major European markets. But as I've mentioned before, we are being measured in our investment given the low price point in Europe and have chosen to manage the EU market on a breakeven basis. Recall that ChemoSat has a broader pan solid tumor device label and some of our European sites have over a decade's worth of experience with ChemoSat. The value of Europe in the short to medium term is as trial sites and a source of publications, both in metastatic uglial melanoma and other tumor types.

Speaker 2

These activities can support both EU and U. S. Adoption. In addition to the significant commercial activity, we continue to support both internal and external efforts to add to the growing body of evidence that the PHD procedure, whether utilizing melflin delivered by Delkast chemoSat or the hepato kit is an important treatment option for patients with liver dominant UV melanoma as well as potentially other liver dominant cancers. In the Q2, we announced the publication of key results from the pivotal Phase III focused trial in hepatot kit in patients with unresectable metastatic uveal melanoma in the journal Annals of Surgical Oncology.

Speaker 2

We expect additional results from the FOCUS study to be presented and published in coming months. For example, an efficacy analysis in clinically important subgroups of patients in the FOCUS study has been accepted as a poster presentation at the upcoming ESMO conference in September. As we continue to roll out commercial use of HEBSADA in the U. S, we are also engaging medical oncologists in the U. S.

Speaker 2

And EU to discuss integration of hepato into treatment algorithms in combination sequencing with available treatment options in metastatic uveal melanoma. There is significant interest in the medical community to evaluate Hepsato in different treatment settings. As an example, I would like to point to a recent single case publication published in Frontiers in Oncology on successful treatment of a metastatic UV melanoma patient with chemocept following failure on immune checkpoint inhibitors and giventafrost. As I mentioned a moment ago, we're expecting a new IIT to enroll and start treatments of patients in Sweden this quarter. This IIT will evaluate sequencing of immune checkpoint inhibitors ipilimumab and nivolumab or ipinilo followed by ChemoSat treatment and compare against therapy with ipinivo as the control.

Speaker 2

This IIT is the second IIT, the first being Japan, which evaluates ipadivo first in sequence with ChemoSET with ChemoSET as a control. In discussions with medical oncologists, we are aware that physicians and patients are very interested in exploring hepcidder or chemoceptin in combination with immunotherapy based on a body of published evidence of possible synergies between chemotherapy and immune therapy in solid tumors. We have heard multiple anecdotal reports of physicians utilizing chemo set and immunotherapy in combination or sequence without waiting for the completion and publication of the CHOPAN study results. On that note, the CHOPAN study continues to progress with 70 of the total planned 76 patients enrolled. Currently, the investigators are anticipating final analysis of the primary endpoint to occur in mid-twenty 25 with presentation of results in the second half of 2025.

Speaker 2

As a reminder, the primary endpoint of the SHOPAN trial is progression free survival at 1 year. This analysis depends on collecting the appropriate number of events, so the timelines for data readout by definition are somewhat uncertain. We continue to plan to initiate 1 or more clinical studies of hepatocemicide in an additional indication over the next 6 months and recently conducted 2 scientific advisory boards focused on colorectal and breast cancer to better define the development path. We will provide updates on our clinical development plan later this year. I will now hand the call over to Sandra to share some details on our financial position.

Speaker 2

Sandra?

Speaker 3

Thank you, Gerard. Revenue from our sales of HAPSADA were $6,600,000 and ChemoSat were $1,200,000 for the 3 months ended June 30, 2024, compared to $500,000 for ChemoSat during the same period in 2023. Our gross margins were 80% in the 2nd quarter. For the 3 months ended June 30, 24, research and development expenses were $3,400,000 compared to $3,600,000 for the 3 months ended June 30, 2023. The change in research and development expenses is primarily due to a decrease in clinical trial activities, offset by an increase in personnel related expenses in medical affairs and regulatory costs associated with an improved product.

Speaker 3

For the 3 months ended June 30 this year compared to the same period in 2023, selling, general and administrative expenses increased to $6,800,000 from $4,800,000 The increase is due to activity for commercial launch, including marketing related expenses and additional personnel team. We ended Q2 with $19,900,000 in cash and investments and cash used in operations was approximately $4,500,000 in the Q2. On August 1, the loan with Avenue fully matured and final payment was made. We believe that our current financial resources are adequate to fund operations until the company achieved $10,000,000 in U. S.

Speaker 3

Quarterly revenue, which would likely trigger a warrant exercise resulting in $25,000,000 in proceeds. This $25,000,000 should be sufficient to fund the company until we become cash flow positive under current levels of research and development expenses. As Gerrard previously mentioned, we remain confident we will achieve $10,000,000 in U. S. Quarterly revenue by the Q4 of this year.

Speaker 3

That concludes our prepared remarks. And I'd ask the operator to open the phone lines for Q and A. Can you please check for questions?

Operator

Thank you. The first question comes from the line of John Newman with Canaccord Genuity. Please go ahead.

Speaker 4

Hi there. Congratulations on the quarter and thank you for taking my question. I know it's still a bit early in the launch, but could you comment on what you're seeing in terms of the mean number of treatments for HEBSATO? And just kind of curious as to how you would expect that trend to progress over the next, say, 12 to 24 months? Thanks.

Speaker 2

Sure. So it's anecdotal at best, given we're really getting this from the reps and the clinical support specialists who are in most of the procedures. But it seems like most patients are progressing on to 2, 3, 4, 5 or more. It's too early now to say whether or not it will match what we saw in the trial, which was 4.1 on average. But I suspect we'll do at least that well over time.

Speaker 2

But no indication that it will be lower than that at this point.

Speaker 4

Okay, great. And if I could sneak in one additional question. It seems like there's a lot of potential for HEBSATO beyond the additional approval. You spoke a bit about additional trials beyond SHOPEN. Just curious, do you expect that those trials would be sort of smaller single arm studies or would you expect that maybe some of those studies might also have control arm?

Speaker 4

Thanks.

Speaker 2

Yes, I think we're going to do a mix of things. So Voya right now is working with both advisory committees to think through larger randomized studies with control arms as well as single and multi center investigator initiated trials. And those would probably more likely be single arm, although some of those have the control as well. So I think you'll see a mix of things from this ranging from sponsored trials that are randomized at the control arm. We might do some trials.

Speaker 2

We have some trials in mind that would look at historical data. So a single arm with a control arm being prespecified, so like a registry data, for example. So it will be a mix of things. And the goal, again, will be a mix as well. The goal will be ranging from giving adequate data so physicians can make an informed judgment for certain patients, whether or not they want to treat and try to get reimbursed for the patients to informing potential guidelines down the road, all the way to trying to expand the label.

Speaker 2

So it will be a mix.

Speaker 4

Great. Thank you.

Operator

Thank you. Next question comes from the line of Marie Thibault with BTIG. Please go ahead.

Speaker 5

Hi, Gerard. Hi, Sandra. Very nice quarter this quarter. I wanted to dig a little bit on the average treatments per center metric. Thank you for giving us that detail.

Speaker 5

If we were to strip out the highest volume center, I don't know if it's still Moffett, I know it was last quarter. Is there a way to think about the average for kind of that remaining group? And you mentioned that they are pausing just to check on billing and things. Is everything going smoothly on that front? I know with the J code going into effect that was of course supposed to help quite a bit.

Speaker 2

Yes. Let me answer the second question first. I have heard of no fundamental problem with reimbursement to hospitals when they do things right. I have heard of a couple of cases where they've done things wrong and they've had to go back and fix it and then get paid. But if they do things right, they get paid.

Speaker 2

And if they don't, they always have the opportunity to go back, which takes a little bit longer. So no fundamental issue there that I've seen at all. Everything's been very positive. In terms of the average treatment rates, I'm going to hesitate from giving breaking it down to that level. I will say if you stripped out the Moffitts and the Thomas Jefferson, yes, the average treatment per week would drop.

Speaker 2

But I do think most centers will eventually do at least 2 a month and many will be more than that. Thomas Jefferson and Moffett clearly are bringing the averages up. In addition, as new centers come on, not all of them, but many of them seem to do a couple of patients then wait and then start going to hit the gas. So those newer centers really will drive, I think, the average downward pressure on the average, but maturing centers will keep the average kind of flat. So net net, that's why I think it will be somewhere between 1.5% to 2% for the balance of the year.

Speaker 5

Okay. That's really helpful. For a follow-up here, wanted to underscore how good your margins were this quarter, both gross margins and OpEx control. Help us think about the sustainability of some of that. Are you needing to add more sales reps to kind of keep up with your launch plans?

Speaker 5

Was there a reason the control is so good on the operating spend side? Just any more detail you can give us there. And thanks for taking the questions.

Speaker 2

Sure. I think we're fairly disciplined on the OpEx side. A lot of the players here have come from another similar company who kind of know spend money wisely. We don't need a huge sales force to reach all the centers. This is going to be a specialty product that is small number of centers.

Speaker 2

I think in the past, I talked about maybe getting to 25 to 30. Our thinking is evolving there. We might decide to get to more like 35 or 40. That might have a marginal increase on SG and A relative to where we are now, but not a huge increase. In terms of cost of goods, we're great for 3, 4 years before we have to do any meaningful type of CapEx, I believe.

Speaker 2

So we're in good shape there. So I think the biggest variable really is, and I'm making preempting a question is R and D spend. How much do we decide that we want to invest into R and D? We're going to be very thoughtful about that, but there's no doubt we will increase R and D at some point for some additional trials. It would just be we'd be remiss if we didn't, because this product has tremendous potential in many other much larger indications.

Speaker 2

But I'm not going to forecast what that's going to be a year and a half out from now. I'll just say, look, we're going to be try to be very prudent And we understand there's an E in EPS and I mean, an S in EPS, excuse me, in terms of number of shares. So we're going to be very prudent, try to keep the cost down, so we really don't have to raise much more money going forward.

Speaker 5

Very good. Thank you.

Operator

Thank you. Next question comes from the line of swam Pukularamakanth with H. C. Wainwright. Please go ahead.

Speaker 6

Thank you. Good afternoon, Umer. Regarding the center activations, now that you have 8 centers activated or almost 10 by the end of this month, what are the learnings from the if there's any push or pull on it and how is that helping you not only educate internally, but also the preceptors so that the next set of activations go smooth?

Speaker 2

Yes. I don't think there's any dramatic learnings aside from we need to address approach stakeholders kind of in parallel and really help try to educate of the stakeholders in the hospitals and get ahead of kind of the various committee approvals and stuff. The preceptorship training stuff is really just a Rubik's cube of scale scheduling. As we get further along and we have more proctors available and people who can do preceptor shifts, it will get a bit easier. But right now, it's just difficulty in scheduling.

Speaker 2

Kevin, I don't know if you want to chime in about any learnings in terms of site activation, pre sector ship or anything like that.

Speaker 7

Sure. Thanks, Gerard. Gerard, I like the analogy, the Rubik's cube of scheduling. And so the more sites that we have active and the more procedures that we have, it lessens the or it increases, I should say, it increases the opportunities for preceptorships and proctorships. So in that respect, it should make the account activation cycle a bit easier.

Speaker 7

The other thing are 8 to 10 centers that we're working with right now. It allows for peer to peer conversations that kind of happen organically behind the scenes. So physicians call each other and hospitals do for some manner of checking on reimbursement and understanding how to set things up. So net net of all of this is that when these centers are will help us and should kind of streamline the activation process as we go forward with the second half of the year.

Speaker 6

Thank you. Regarding the NTAP that you received, the hepzara kit received just earlier this month, how does that benefit in terms of adoption? And would that help in any ways in terms of increasing the number of procedures per center? Yes.

Speaker 2

I don't think getting NTAP is going to make much of a difference in terms of uptake. I think it is helpful for the hospitals when they have the infrequent inpatients. It will lessen the financial burden on the hospital. It's a rather complex formulary. They have to hit a certain loss amount and it covers a certain percentage up to a certain percentage, which I don't think it's worth going into that level of detail, because I don't think it's that critical.

Speaker 2

I think the most important thing or telling thing is it's more of a sign of how innovative this therapy truly is. People look at it's milk blend, it's a device, etcetera. But the bar to get the new technology add on payment is pretty high. You really do need to prove that you're an innovative therapy doing something that nothing else does is out there. And I think it's fantastic that we got it.

Speaker 2

And I think although it seems unrelated, the physician reaction we're getting from the radiologists and oncologists reviewing the product and the response rate they're seeing, they're incredibly positive. So, it's just it shows that, yes, this is a filter, it's old school chemo. It is truly something new that's making a real difference for patients. And I think that's why we got the NTAP. It is a modest tailwind, but it's not that big of a deal.

Speaker 2

We don't need it. Okay.

Speaker 6

Thank you. One last question from me on the UK reimbursement, Since there are couple hospitals, if I remember correctly, from the U. K. That have used ChemoSat for a longer time than others. How is that going to play into the reimbursement review when it comes time?

Speaker 2

Yes, I have no doubt we're going to get reimbursement. They went from a semi annual review to an annual review. That was a surprise to us. That's what pushed it back into next year. That just was a recent change in how often they do the review.

Speaker 2

But we'll get reimbursement. I have no doubt about that. The question is what will the reimbursement be? I don't have high hopes that that will be a significant step up from where we are right now. But again, as I mentioned before, we're going to manage Europe on a kind of roughly breakeven basis.

Speaker 2

But we're going to continue to invest in there on a measured basis, because I think it's as clinical sites and as sources generate publications, it's a very, very important strategic asset to the company.

Speaker 6

Perfect. Thank you very much, Gerard.

Operator

Thank you. Next question comes from the line of Sudan Loganichan with Stephens. Please go ahead.

Speaker 8

Hi, Gerrard, Sandra and Velocast team. Congrats on a great quarter. Two questions. My first one is regarding the marketing strategy. Is the main focus geared towards selling the kit to hospitals to bring on more additional sites or trying to focus them more towards the patient and physician awareness?

Speaker 8

And then as you go into next year and progress this launch, will there be any changes to that marketing strategy? And then secondly, at what quarterly and yearly revenue run rate and OpEx range do you anticipate you need to be at to achieve a breakeven or positive EPS? I understand you might also have aspirations and other indications for its etiquette, but is break getting to breakeven a cash flow positive or at least a track towards that a potential goal to achieve prior to taking on new clinical endeavors?

Speaker 2

Sure. I think, Sandra, why don't you pick up where you think we need to be at to hit breakeven, okay, on a quarterly basis under current R and D spend?

Speaker 3

Yes. Currently, probably around the 60 to 80 kits, just depending a quarter in order to be breakeven or cash flow positive. Obviously dependent on additional SG and A, marketing spend and R and D that will be incurred the rest of this year. But I think we're well on the course of becoming cash flow positive, hopefully by Q1 of 2025.

Speaker 2

And that's about $13,000,000 a quarter in revenue?

Speaker 1

Yes.

Speaker 2

All right. Now in terms of the focus, and market, I mean right now I think Kevin chime in if you disagree, we're probably focuses 80% site activation, 20% trying to get patients to the sites That will switch over time. But all elements of the marketing mix are important at the moment. Kevin, maybe I don't know if you want to give a couple of sentences about our priorities now and how that might evolve over the next year, year and a half.

Speaker 7

Sure. And I think with the patient population that we have right now, one of our main goals is to that 20% is to drive awareness and increase patient access to what we think is a wonderful option for these patients. And while opening sites is important, it's not our main goal. Our main goal is not to open as many sites as we can. As Gerard pointed out in his remarks, we've started with a goal of 20 and with our ultimate goal probably roughly around 40 sites.

Speaker 7

And it's more the quality of sites. Are we going to the correct sites? Are we giving patients access at these sites. So that's been our focus, opening the right sites and getting patients access to those sites.

Speaker 8

Thanks. I appreciate it.

Operator

Thank you. Next question comes from the line of Chase Kniekebacher with Craig Hallum Capital Group. Please go ahead.

Speaker 9

Good afternoon, everyone. Thanks for taking the questions. Just first from me, are there any other high end early adopters in the pipeline, kind of like Moffett or Thomas Jefferson? Or should we think of kind of everyone else from here, as those that maybe pause a bit after a couple of patients and kind of generally drag down that average kits per center per month number over the 1st quarter or so of them being active?

Speaker 2

I think there's a third surprise center to us that I wouldn't say that they're at that level, but might approach it given some recent activity. And I think there'll be a number of others that will reach that level. I think some of the centers we're opening that weren't at that level in terms of a book of business. Once they have our treatments, they will increasingly become kind of a destination for a lot of patients. So I don't think that I don't think we're going to have a ton of centers doing 6 a week.

Speaker 2

But will we end up having quite a I mean 6 a month, excuse me, will we end up having quite a few centers that are doing maybe 1 a week and quite a few centers being more than 4 or 5? Yes, I think so, eventually. So if you look at the kind of the Pareto analysis of centers, those are the big guys who you mentioned. But I think a lot of centers, once they have our therapy, will end up treating patients, maybe that aren't appropriate for our therapy, but they're going to start bringing them in. So they'll start becoming destinations.

Speaker 9

Should we think of kind of a max level kind of per week treatments that some of those high adopters could do? I mean, any way for us to kind of think about that of kind of what the constraint is on the high end? And then second, of the centers that are kind of awaiting that initial commercial treatment scheduling, do we get a sense of kind of how long it takes to activate those patients? I know we kind of gave a lot of numbers on the call, so forgive me if I'm making you repeat yourselves, but just kind of those 4, for example, that we're just kind of awaiting the schedules to line up? Do we have a kind of a general kind of feel for how long that takes?

Speaker 2

No, it's been all over the map. And that's why I was off a bit in my projections. I thought we'd have 10 by the end of last quarter and we didn't. We had 7, now we're at 8. And in about 3 or 4 weeks, we should be at 2 or 3 weeks, we should be attentive, if nobody patient doesn't get a cold and all the proctors can show up, etcetera.

Speaker 2

It really is all over the map. In terms of what you think of what is a max or a run rate, we have a couple of centers in Europe that if it's not summer vacation, are doing pretty regularly 1 a week. And that seems to be kind of a natural high volume rate for centers, although we've had we had one center recently do 3 in one day, believe it or not. So that center may end up being a 6 a month, 7 a month type place. So I think as people get used to this or are willing to train a second team or have a couple of backup people, they might end up doing 6 or 7 a month.

Speaker 2

But right now, I think 4 months will likely be what the high end does for a bit and others are going to be 1 or 2 a month. I think eventually we'll see some sites that regularly do 1 to 2 a week, but that'll take a bit of time. And again, we saw Center just the other, I think, 2 weeks ago that did or last week, they did 3 in one day. So, they were able to push them through.

Speaker 9

Got it. That's helpful color. And then just last for me. Just maybe speak to a little bit about I know it's early, but the progress that you're having in the community, kind of driving referrals to some of these centers and then maybe kind of an early look at how your therapy is going to interact with those patients that are eligible for tibentoFust. Are those kind of patients who are eligible getting tibentoFust first?

Speaker 9

Or is this something where physicians are viewing it kind of in line treatment? Just kind of give me an early look there.

Speaker 2

We've had patients before Tebby and we've had patients after Tebby. And it really has more to do with whether the doc believes that liver directed therapy should go first because this liver match is usually what these patients to come to. So if they're going to prioritize treatment, sometimes want to prioritize liver directed therapy. So it's all over the map and it will settle out over time probably one way or another. But most patients do live long enough to get more than one line of therapy.

Speaker 2

So whether they go first on Teva or first on us, I think patients who are HLA-two positive should get both. It's probably the right thing for the patients. In terms of referrals, it's still early days. Bolio's team and Kevin's team are both working on Dolio's medical affairs team and Kevin's commercial team are both working on setting up referral patterns. We've had, I don't know, quite a few referrals to date.

Speaker 2

They're usually peer to peer referrals. So a lot of times we've been getting referrals from centers that are waiting to finish their preceptorships or finishing up their various approval committees they need to have. They have a patient they want to have treated. They send them to another site knowing the patient is going to come back to them hopefully once the fall the approvals occur at their center. So we've seen those peer to peer referrals.

Speaker 2

And we've also sent some patients directly due to phone calls we've made and such 100 treating sites. In terms of a good well oiled machine referral process, we're developing that right now. That's something that will become increasingly important. We're confident we can do it. It's going to involve a lot of direct patient things work through advocacy centers.

Speaker 2

The advocacy groups are very excited about the product. So we'll work with them so the patients know where this is available. We have reasonable data as to who's treating these patients. So we know who has just one of them, just 2 of them, just 3 of them and we are we have developed process where through e mails, phone calls, perhaps surprise visits. We try to get in front of these docs to tell them about, about hepcidl kit.

Speaker 2

Because each of these patients is so valuable, it makes sense to hunt down to that level of n equals 1, equals n equals 2 or 3. But we recognize the importance of that. We're also developing programs where the patient has a reason to get directly in touch with a third party that we work with. Maybe it's help with co pays, travel, etcetera. But through that process, we'll probably get involved with docs who have smaller numbers of patients and that will help us with referrals there.

Speaker 2

So it's going to be a kind of a multi spoke effort. Still early days to declare, say how well it's working, but we are going to be focused on that.

Speaker 9

Got it. Thanks, Gerard. And congrats again on the great early progress here.

Speaker 3

Thank you.

Operator

Thank you. This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation.

Remove Ads
Powered by Quartr
Earnings Conference Call
Delcath Systems Q2 2024
00:00 / 00:00
Remove Ads